These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 29399049)

  • 21. Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center.
    Green SF; Hare N; Kassam M; Rugg-Gunn F; Koepp MJ; Sander JW; Rajakulendran S
    Epilepsy Behav; 2022 Oct; 135():108868. PubMed ID: 35985166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: A phase III randomized, double-blind, placebo-controlled trial.
    Inoue Y; Tiamkao S; Zhou D; Cabral-Lim L; Lim KS; Lim SH; Tsai JJ; Moseley B; Wang L; Sun W; Hayakawa Y; Sasamoto H; Sano T; McClung C; Bass A
    Epilepsia Open; 2024 Jun; 9(3):1007-1020. PubMed ID: 38576178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and Electroencephalography Assessment of the Effects of Brivaracetam in the Treatment of Drug-Resistant Focal Epilepsy.
    Savastano E; Pulitano P; Faedda MT; Davì L; Vanacore N; Mecarelli O
    Cureus; 2021 May; 13(5):e15012. PubMed ID: 34131547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy.
    Gillis RME; Wammes-van der Heijden EA; Schelhaas HJ; Tan IY; Festen DAM; Majoie MHJM
    Acta Neurol Belg; 2021 Jun; 121(3):677-684. PubMed ID: 32157673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures.
    Klein P; Schiemann J; Sperling MR; Whitesides J; Liang W; Stalvey T; Brandt C; Kwan P
    Epilepsia; 2015 Dec; 56(12):1890-8. PubMed ID: 26471380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Sands ZA; Vandenplas C; Gillard M
    Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.
    Foo EC; Geldard J; Peacey C; Wright E; Eltayeb K; Maguire M
    Epilepsy Behav; 2019 Oct; 99():106505. PubMed ID: 31493736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
    Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
    Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial.
    Van Paesschen W; Hirsch E; Johnson M; Falter U; von Rosenstiel P
    Epilepsia; 2013 Jan; 54(1):89-97. PubMed ID: 22813235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial.
    Ben-Menachem E; Baulac M; Hong SB; Cleveland JM; Reichel C; Schulz AL; Wagener G; Brandt C
    Epilepsy Res; 2021 Feb; 170():106526. PubMed ID: 33461041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
    Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
    Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging drugs for partial-onset epilepsy: a review of brivaracetam.
    Gao L; Li S
    Ther Clin Risk Manag; 2016; 12():719-34. PubMed ID: 27217762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
    Ben-Menachem E; Mameniškienė R; Quarato PP; Klein P; Gamage J; Schiemann J; Johnson ME; Whitesides J; McDonough B; Eckhardt K
    Neurology; 2016 Jul; 87(3):314-23. PubMed ID: 27335114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial.
    Arnold S; Laloyaux C; Schulz AL; Elmoufti S; Yates S; Fakhoury T
    Epilepsy Res; 2020 Oct; 166():106404. PubMed ID: 32731118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.
    Steinig I; von Podewils F; Möddel G; Bauer S; Klein KM; Paule E; Reif PS; Willems LM; Zöllner JP; Kunz R; Runge U; Kurlemann G; Schubert-Bast S; Rosenow F; Strzelczyk A
    Epilepsia; 2017 Jul; 58(7):1208-1216. PubMed ID: 28480518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis.
    Brandt C; Klein P; Badalamenti V; Gasalla T; Whitesides J
    Epilepsy Behav; 2020 Feb; 103(Pt A):106864. PubMed ID: 31937513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience.
    Steinhoff BJ; Staack AM
    Ther Adv Neurol Disord; 2019; 12():1756286419873518. PubMed ID: 31523280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and tolerability of adjunctive brivaracetam in patients with focal seizures: Second interim analysis of 6-month data from a prospective observational study in Europe.
    Steinhoff BJ; Christensen J; Doherty CP; Majoie M; De Backer M; Hellot S; Leunikava I; Leach JP
    Epilepsy Res; 2020 Sep; 165():106329. PubMed ID: 32623096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies.
    Brodie MJ; Whitesides J; Schiemann J; D'Souza J; Johnson ME
    Epilepsy Res; 2016 Nov; 127():114-118. PubMed ID: 27589414
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.